You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • THU0130 Distinct Biomarkers Enrich for Clinical Response to Tocilizumab (TCZ) and Adalimumab (ADA) in Adacta: A Head-to-Head Monotherapy Study in Patients (PTS) with Methotrexate (MTX)-IR Rheumatoid Arthritis (RA)

Citation Tools

Article menu
Download PDFPDF
Poster Presentation
Rheumatoid arthritis - prognosis, predictors and outcome
THU0130 Distinct Biomarkers Enrich for Clinical Response to Tocilizumab (TCZ) and Adalimumab (ADA) in Adacta: A Head-to-Head Monotherapy Study in Patients (PTS) with Methotrexate (MTX)-IR Rheumatoid Arthritis (RA)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Herman A, Musselman D, Fischer S, et al
THU0130 Distinct Biomarkers Enrich for Clinical Response to Tocilizumab (TCZ) and Adalimumab (ADA) in Adacta: A Head-to-Head Monotherapy Study in Patients (PTS) with Methotrexate (MTX)-IR Rheumatoid Arthritis (RA)
Annals of the Rheumatic Diseases 2013;72:A206.